Cost-effectiveness of abatacept, rituximab, and TNFi treatment after previous failure with TNFi treatment in rheumatoid arthritis: a pragmatic multi-centre randomised trial

INTRODUCTION: For patients with rheumatoid arthritis (RA) whose treatment with a tumour necrosis factor inhibitor (TNFi) is failing, several biological treatment options are available. Often, another TNFi or a biological with another mode of action is prescribed. The objective of this study was to c...

詳細記述

保存先:
書誌詳細
出版年:Arthritis Res Ther
主要な著者: Manders, Sofie HM, Kievit, Wietske, Adang, Eddy, Brus, Herman L, Moens, Hein J Bernelot, Hartkamp, Andre, Hendriks, Lidy, Brouwer, Elisabeth, Visser, Henk, Vonkeman, Harald E, Hendrikx, Jos, Jansen, Tim L, Westhovens, Rene, van de Laar, Mart AFJ, van Riel, Piet LCM
フォーマット: Artigo
言語:Inglês
出版事項: BioMed Central 2015
主題:
Research Article
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC4489004/
https://ncbi.nlm.nih.gov/pubmed/25997746
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13075-015-0630-5
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料